494 related articles for article (PubMed ID: 30508182)
1. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
3. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
4. Novel targets and interaction partners of mutant p53 Gain-Of-Function.
Aschauer L; Muller PA
Biochem Soc Trans; 2016 Apr; 44(2):460-6. PubMed ID: 27068955
[TBL] [Abstract][Full Text] [Related]
5. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
6. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane.
Phatak V; von Grabowiecki Y; Janus J; Officer L; Behan C; Aschauer L; Pinon L; Mackay H; Zanivan S; Norman JC; Kelly M; Le Quesne J; Muller PAJ
Cell Death Dis; 2021 Feb; 12(2):207. PubMed ID: 33627632
[TBL] [Abstract][Full Text] [Related]
8. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
Xu J; Wang J; Hu Y; Qian J; Xu B; Chen H; Zou W; Fang JY
Cell Death Dis; 2014 Mar; 5(3):e1108. PubMed ID: 24603336
[TBL] [Abstract][Full Text] [Related]
9. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.
Zhao Y; Ding L; Wang D; Ye Z; He Y; Ma L; Zhu R; Pan Y; Wu Q; Pang K; Hou X; Weroha SJ; Han C; Coleman R; Coleman I; Karnes RJ; Zhang J; Nelson PS; Wang L; Huang H
EMBO J; 2019 Mar; 38(5):. PubMed ID: 30723117
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
12. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
13. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
14. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
17. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells.
Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G
J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
20. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]